Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'Uncomfortable' Panel Backs Amgen Biosimilar, But Uphill Battle To Sway Docs, Public

Executive Summary

A tense advisory committee meeting, where many of the panelists admitted they lacked a complete understanding about biosimilars and patient advocates expressed anxiety over the products, could signal difficulties with adoption and success in the marketplace.

You may also be interested in...



Amgen Plugs Away On Repatha, With Hope For New Monthly Product

In a very strong second-quarter earnings report, Amgen reports just $27m in worldwide sales for cholesterol-busting PCSK9 inhibitor Repatha, as reimbursement continues to present a big hurdle.

Samsung Seeks Third Anti-TNF Biosimilar Launch In Europe

After receiving regulatory approvals in Europe for its biosimilar versions of etanercept and infliximab earlier this year, South Korea's Samsung Bioepis is now looking to add adalimumab to it and partner Biogen’s growing portfolio.

Samsung Seeks Third Anti-TNF Biosimilar Launch In Europe

After receiving regulatory approvals in Europe for its biosimilar versions of etanercept and infliximab earlier this year, South Korea's Samsung Bioepis is now looking to add adalimumab to it and partner Biogen’s growing portfolio.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel